Abstract
Purpose Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy, however, only a fraction of the patients respond to it completely. To prevent over-treating patients with a toxic drug, there is an urgent need for biomarkers capable of predicting treatment response before administering the therapy. In this retrospective study, we developed interpretable, deep-learning based biomarkers to predict the pathological complete response (pCR, i.e. the absence of tumor cells in the surgical resection specimens) to neoadjuvant chemotherapy from digital pathology H&E images of pre-treatment breast biopsies.
Experimental Design Our approach consists of two steps: In the first step, using deep learning, mitoses are detected and the tissue segmented into several morphology compartments including tumor, lymphocytes and stroma. In the second step, computational biomarkers are derived from the segmentation and detection output to encode slide-level relationships between the morphological structures with focus on tumor infiltrating lymphocytes (TILs). We developed and evaluated our method on slides from N=721 patients from three European medical centers with triple-negative and Luminal B breast cancers.
Results The investigated biomarkers yield statistically significant prediction performance for pCR with areas under the receiver operating characteristic curve between 0.66 and 0.88 depending on the cancer subtype and center.
Conclusion The proposed computational biomarkers predict pathological complete response, but will require more evaluation and finetuning for clinical application. The results further corroborate the potential role of deep learning to automate TILs quantification, and their predictive value in breast cancer neoadjuvant treatment planning.
Competing Interest Statement
JvdL was a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last five years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands. FC was Chair of the Scientific and Medical Advisory Board of TRIBVN Healthcare, France, and received advisory board fees from TRIBVN Healthcare, France in the last five years. He is shareholder of Aiosyn BV, the Netherlands. MB is medical advisor at Aiosyn BV. All other authors declare no conflict of interest.
Funding Statement
This project was funded by the Dutch Cancer Society (KWF, PROACTING project number 11917), and partly received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825292 (ExaMode, htttp://www.examode.eu/).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of the slides from the Radboud University Medical Center for the study was approved by the Ethical Committee of the Radboud University Medical Center (2020-7103). The use of the slides from the Netherlands Cancer Institute for the study was approved by the institutional review board of the Netherlands Cancer Institute under number CFMPB737. The use of the slides from the IRCCS Sacro Cuore Don Calabria Hospital for the study was approved by the Ethic Committee for Clinical Research of the Provinces of Verona and Rovigo under number 25046.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵@ francesco.ciompi{at}radboudumc.nl
Table 1 revised to correct the RUMC+SCDC TNBC evaluation results for the biomarkers cTILs and MTR - the AUC was erroneously inverted (manuscript v2 had still the same error). These changes have no effect on the papers message or conclusion.
Data Availability
Due to data agreement limitations, the patient data used to develop and validate the biomarkers cannot be shared. The algorithm to compute the biomarkers ITR, LTR and cTILs was made available on the Grand Challenge-platform and can be accessed upon request for research purposes.
